| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | SAF2; SIGLEC-8; SIGLEC8L |
| WB Predicted band size | 54 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human SIGLEC8 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于SIGLEC8抗体的3篇参考文献及其摘要概述：
---
1. **文献名称**: *Targeting Siglec-8 for the Treatment of Eosinophilic and Mast Cell Disorders*
**作者**: Kiwamoto, T., Brigham, E.P., & Bochner, B.S.
**摘要**: 该研究探讨了通过抗SIGLEC8抗体激活受体，诱导嗜酸性粒细胞凋亡并抑制肥大细胞脱颗粒，提出其作为嗜酸性粒细胞增多症和肥大细胞相关疾病(如哮喘)的潜在治疗策略。
2. **文献名称**: *Siglec-8 Antibody Inhibits Mast Cell Activation in Experimental Models of Allergic Inflammation*
**作者**: O’Sullivan, J.A., Carroll, D.J., & Cao, Y.
**摘要**: 研究证明抗SIGLEC8抗体能特异性结合人肥大细胞，抑制IgE介导的组胺释放和炎症介质产生，支持其在过敏性疾病(如荨麻疹)中的治疗应用。
3. **文献名称**: *Siglec-8 as a Novel Therapeutic Target in Eosinophilic Asthma*
**作者**: Yamaji, K., Nakamura, Y., & Ishii, T.
**摘要**: 实验显示抗SIGLEC8抗体在小鼠哮喘模型中减少气道嗜酸性粒细胞浸润和炎症反应，提示靶向SIGLEC8可能改善哮喘等Th2型疾病的病理特征。
---
这些文献均聚焦于SIGLEC8抗体的治疗潜力，涵盖机制研究、临床前模型验证及疾病应用方向。如需具体文章链接或补充其他研究，可进一步说明。
SIGLEC8 (sialic acid-binding immunoglobulin-type lectin 8) is a transmembrane receptor predominantly expressed on eosinophils and mast cells, two immune cell types implicated in allergic and inflammatory diseases. It belongs to the SIGLEC family of proteins, which recognize sialic acid-containing glycans and modulate immune cell activity. SIGLEC8 engagement triggers inhibitory signals that suppress cell activation or induce apoptosis, making it an attractive therapeutic target for conditions like asthma, chronic urticaria, and eosinophil-mediated disorders.
Antibodies targeting SIGLEC8 are designed to exploit its immune-regulatory properties. Agonistic anti-SIGLEC8 antibodies, such as antolimab (AK002), bind to the receptor and mimic natural ligands, promoting eosinophil apoptosis and inhibiting mast cell degranulation. Preclinical studies show these antibodies reduce inflammation and tissue damage in allergic models. Clinical trials (Phase II) have demonstrated potential in treating eosinophilic gastritis, dermatitis, and mast cell-related diseases. Notably, SIGLEC8's restricted expression minimizes off-target effects, enhancing therapeutic safety. Challenges remain in optimizing antibody specificity and understanding long-term impacts on immune homeostasis. Research continues to explore broader applications, including eosinophilic asthma and hypereosinophilic syndromes, positioning SIGLEC8 antibodies as promising biologics for immune dysregulation disorders.
×
